ArticleFrontiers in immunology2026
Decoding clinical heterogeneity and age-related coronary risk in incomplete Kawasaki disease: a multicenter cluster analysis and structural equation modeling study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To identify pretreatment clinical subphenotypes in incomplete Kawasaki disease (iKD) and examine their associations with post-IVIG coronary outcomes. Methods: We retrospectively analyzed 1,619 iKD patients from six centers. Hierarchical clustering was performed using 11 pretreatment clinical and laboratory variables, with coronary measures excluded from cluster derivation. Post-IVIG coronary outcomes were subsequently compared across clusters. Logistic regression, exploratory structural equation modeling (SEM), and LOESS analyses were used to examine factors associated with coronary artery aneurysm (CAA). The same clustering framework was also applied to the entire KD cohort (n=6,264). Focused sensitivity analyses excluded patients whose retrospective iKD classification depended on coronary findings and separately evaluated pre-IVIG coronary abnormalities and newly developed or worsening abnormalities after IVIG. Results: Four clinically distinct iKD clusters were identified. C1 showed greater systemic inflammation, C2 was characterized by younger age, longer pretreatment fever duration, and marked thrombocytosis, C3 by prominent hepatobiliary involvement, and C4 by a relatively low-inflammatory profile. C2 had the highest CAA prevalence (68.9%) and greatest coronary burden, whereas C3 had the highest IVIG-resistance rate (12.7%). Younger age, longer pretreatment fever duration, fewer clinical manifestations, lower albumin, lower hemoglobin Z-score, and lower neutrophil ratio remained independently associated with CAA. SEM showed a strong direct association of age with CAA and only a small indirect association through symptom count and pretreatment fever duration. In the whole-KD analysis, iKD was unevenly distributed across the independently derived clusters. The major cluster characteristics and the greater post-IVIG coronary burden of C2 remained evident after exclusion of patients whose iKD classification depended on coronary findings. Conclusions: iKD comprises clinically heterogeneous pretreatment phenotypes associated with different coronary and treatment-response profiles. The coronary vulnerability of younger patients appears multifactorial rather than explained solely by longer pretreatment fever duration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.